Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia.

Blood
B D HarrisonJ Yin

Abstract

Effective presentation of tumor antigens is fundamental to strategies aimed at enrolling the immune system in eradication of residual disease after conventional treatments. Myeloid malignancies provide a unique opportunity to derive dendritic cells (DCs), functioning antigen-presenting cells, from the malignant cells themselves. These may then co-express leukemic antigens together with appropriate secondary signals and be used to generate a specific, antileukemic immune response. In this study, blasts from 40 patients with acute myeloid leukemia (AML) were cultured with combinations of granulocyte-macrophage colony-stimulating factor, interleukin 4, and tumor necrosis factor alpha, and development to DCs was assessed. After culture, cells from 24 samples exhibited morphological and immunophenotypic features of DCs, including expression of major histocompatibility complex class II, CD1a, CD83, and CD86, and were potent stimulators in an allogeneic mixed lymphocyte reaction (MLR). Stimulation of autologous T-cell responses was assessed by the proliferative response of autologous T cells to the leukemic DCs and by demonstration of the induction of specific, autologous, antileukemic cytotoxicity. Of 17 samples, 11 were effective st...Continue Reading

References

Nov 25, 1992·Journal of Immunological Methods·B J KroesenL de Leij
Aug 1, 1989·The Journal of Experimental Medicine·J H JansenH C Kluin-Nelemans
Jul 1, 1983·The Journal of Experimental Medicine·W C Van VoorhisR M Steinman
Nov 5, 1993·Journal of Immunological Methods·L ChangS L Nehlsen-Cannarella
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·L J Zhou, T F Tedder
Aug 1, 1996·The Journal of Experimental Medicine·D BoczkowskiE Gilboa
Jun 1, 1996·Immunology Today·J H PetersF Steinbach
Jun 1, 1997·Immunological Reviews·J H FalkenburgR Willemze
Jun 1, 1997·Immunological Reviews·K A MargolinS J Forman
Mar 27, 1998·Current Opinion in Hematology·J M Austyn
Apr 1, 1998·Nature·J Banchereau, R M Steinman
May 16, 1998·The Journal of Experimental Medicine·L OehlerW Knapp

❮ Previous
Next ❯

Citations

May 13, 2005·Cancer Immunology, Immunotherapy : CII·Marie RobinRose-Ann Padua
May 12, 2005·Cancer Immunology, Immunotherapy : CII·Johannes ScheteligMartin Bornhäuser
Feb 2, 2006·Cancer Immunology, Immunotherapy : CII·Lucas ChanFarzin Farzaneh
Sep 23, 2008·Pathology Oncology Research : POR·Kambiz BagheriSeyyed Mohammad Moazzeni
Feb 2, 2002·Experimental Hematology·Francesca ReDamiano Rondelli
Dec 8, 2004·The Lancet Oncology·Simone MocellinCarlo Riccardo Rossi
Jun 29, 2007·Nature Clinical Practice. Oncology·Ben SprangersAn D Billiau
Sep 13, 2002·Immunology·Joanna Galea-Lauri
Nov 20, 2002·Vox Sanguinis·P H Roddie, M L Turner
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·Fiona J Clark, Ronjon Chakraverty
Jun 13, 2008·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Astrid Marta OlsnesØystein Bruserud
Oct 24, 2002·Current Opinion in Hematology·J H F FalkenburgR Willemze
Jun 4, 2013·Immunotherapy·Nathalie KerkhoffArjan A van de Loosdrecht
Dec 22, 2011·Journal of Biomedicine & Biotechnology·Jian NingDerwood Pamphilon
Dec 1, 2007·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Thanh-Nhan Nguyen PhamJe-Jung Lee
Sep 23, 2006·Expert Review of Vaccines·Jacalyn Rosenblatt, David Avigan
Apr 13, 2006·Expert Review of Vaccines·Matthias Klammer, Patrick H Roddie
Sep 16, 2008·Best Practice & Research. Clinical Haematology·Caroline Duncan, Huw Roddie
Mar 21, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Theresia M WestersArjan A van de Loosdrecht
Aug 26, 2009·Scandinavian Journal of Immunology·A I RomeroK Hellstrand
Apr 18, 2007·Clinical and Experimental Immunology·A J Barrett, K Rezvani
May 22, 2008·British Journal of Haematology·Ilse HoutenbosArjan A van de Loosdrecht
Jul 7, 2007·British Journal of Haematology·Jane RasaiyaahBenjamin M Chain
Dec 15, 2004·Clinical Immunology : the Official Journal of the Clinical Immunology Society·J DeanL Golden-Mason
Aug 22, 2006·Immunobiology·Ilse HoutenbosArjan A van de Loosdrecht
Aug 22, 2006·Immunobiology·Theresia M WestersGert J Ossenkoppele

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.